#Polymerase Chain Reaction (PCR) Market Review | Explore Tumblr Posts and Blogs

pragatisblogs · 2 years

Text

Molecular Diagnostics Market Size to Grow with High CAGR during Forecast Period

Molecular Diagnostics Market Growth:

Washington, D.C., United States: Straits Research's latest report on, Molecular Diagnostics Market - Global Industry Overview and Forecast 2022-2030, highlights potential, risk factor analyses, and enhanced with strategic and tactical decision-making assistance. The growth and regulatory factors impacting information consumption, the availability of highly dependable items in the market, and the improvement in operating efficiency of Molecular Diagnostics industry players. According to the Straits Research, Molecular Diagnostics Market Size Anticipated to grow at a higher CAGR During the Forecast Period.Molecular Diagnostics Market Scope report covers market trends and development, drivers, capacities, technologies, and the changing dynamics of the Molecular Diagnostics Market.

Competitive Landscape

Some of the prominent players operating in the Molecular Diagnostics market are Abbott Laboratories, Agilent Technologies, Siemens AG, Biomérieux Sa, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Illumina, Roche Diagnostics, Hologic, and Qiagen

Get Free Request Sample Report @ https://straitsresearch.com/report/molecular-diagnostics-market/request-sample

Studies explore the effects of COVID-19 on the upstream, midstream, and downstream sectors of the industry. In addition, this analysis provides extensive market estimations by putting an emphasis on data covering numerous factors that encompass market dynamics such as market drivers, market barriers, market opportunities, market risks, and industry news and trends.

This research also provides a dashboard view of prominent Organization, highlighting their effective marketing tactics, market share and most recent advances in both historical and current settings.

Global Molecular Diagnostics Market: Segmentation

As a result of the Molecular Diagnostics market segmentation, the market is divided into sub-segments based on product type, application, as well as regional and country-level forecasts.

By Product & Service

Reagents & Kits

Instruments

Software & Services

By Technology

Polymerase Chain Reaction (PCR)

Isothermal Nucleic Acid Amplification Technology (INAAT)

DNA Sequencing & Next-Generation Sequencing (NGS)

In Situ Hybridization

DNA Microarray

Other Technologies

By Application

Infectious Diseases

Hepatitis

HIV

CT/NG

HAIS

HPV

Tuberculosis

Influenza

Other Infectious Diseases

Oncology

Breast Cancer

Colorectal Cancer

Lung Cancer

Prostate Cancer

Other Cancers

Genetic Tests

Other Applications

By End-User

Hospital & Academic Laboratories

Reference Laboratories

Other End Users

Stay ahead of the competition with our in-depth analysis of the market trends!

Buy Now @ https://straitsresearch.com/buy-now/molecular-diagnostics-market

The following are the report's key features:

It gives useful information on the Global Molecular Diagnostics Market.

Information for the years 2022-2030 is provided.

Market-related important factors are highlighted.

The latest technological innovations, government restrictions, and developments are presented.

This paper investigates advertising and marketing techniques, market trends, and analysis.

Growth projections and analyses by forecast 2030.

The statistical analysis of the market's leading competitors is emphasised.

Molecular Diagnostics Market summary based on extensive study.

Other aspects of the report include:

Provides a complete review of important tactics in numerous firms, with an emphasis on corporate structure, R&D processes, localization strategies, manufacturing capabilities, sales, and performance.

Provides essential product portfolio information, including product planning, development, and positioning.

Analyzes the role of significant market participants, as well as their collaborations, mergers, and acquisitions.

Trending Report:

About Straits Research

Straits Research is dedicated to providing businesses with the highest quality market research services. With a team of experienced researchers and analysts, we strive to deliver insightful and actionable data that helps our clients make informed decisions about their industry and market. Our customized approach allows us to tailor our research to each client's specific needs and goals, ensuring that they receive the most relevant and valuable insights.

Email: [email protected]

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: +1 6464807505, +44 203 318 2846

#Molecular Diagnostics Market #Molecular Diagnostics Market Share #Molecular Diagnostics Market Size #Molecular Diagnostics Market Research #Molecular Diagnostics Industry #What is Molecular Diagnostics?

0 notes

datainsights2022 · 2 years

Text

Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection

An adult and pediatric Zaire ebolavirus infection can be treated with the Zaire ebolavirus-directed human monoclonal antibody Ebanga (ansuvimab-zykl).

Ebanga™ (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP) coordinated human monoclonal immune response for the treatment of Zaire Ebolavirus Infections Drugs Development Market contamination in grown-up and pediatric patients. The treatment is also available to infants born to mothers who test positive for the infection using reverse transcription polymerase chain reaction (RT-PCR).

The Vaccine Research Centre of the National Institute of Allergy and Infectious Diseases (NIAID), a component of the US Government's National Institutes of Health (NIH), was the initial developer of the medication.

Under a patent license agreement for the intellectual property associated with the monoclonal antibody, Ridgeback Biotherapeutics, a biotechnology company based in the United States, received a license for Ebanga (formerly known as mAb114) from the NIAID in December 2018.

Ebanga comes in a single-dose vial containing 400 milligrams of ansuvimab-zykl in the form of an off-white to white lyophilized powder that can be reconstituted for intravenous administration.

Ebanga endorsements Ebanga was conceded vagrant medication assignment and advancement treatment assignment by the US Food and Medication Organization (FDA) for Ebola treatment in May 2019 and September 2019 separately.

The US Biomedical Advanced Research and Development Authority (BARDA) awarded Ridgeback a contract worth $10.9 million in April 2020 to develop ansuvimab for the treatment of Ebola virus disease.

The treatment's improvement has been entirely or to some extent supported by the returns from the US Division of Wellbeing and Human Administrations (HHS), as well as the Workplace of the Associate Secretary for Readiness and Reaction (ASPR) and BARDA.

The FDA received Ridgeback's biologics license application (BLA) for Ebanga in May 2020. Under priority review, this was accepted in July 2020.

In August 2020, Ridgeback started an extended admittance convention for the quick availability of Ebola treatment, ansuvimab, in the Majority rule Republic of the Congo (DRC).

The drug was approved by the FDA in December 2020 for the treatment of adults and children with Zaire ebolavirus infection, including newborns whose mothers tested positive for the virus.

After Regeneron's InmazebTM (atoltivimab, maftivimab, and odesivimab-ebgn), a triple monoclonal antibody cocktail drug that was approved in October 2020, Ebanga is the second medication that has been approved by the FDA for the treatment of the Zaire ebolavirus infection.

Ebola, also known as Ebola virus disease (EVD) or Zaire ebolavirus infection, is an infection brought on by Zaire ebolavirus, one of four species of Ebolavirus. EVD is an uncommon however serious, frequently deadly illness in people, and is endemic to the African mainland.

A collection of viruses belonging to the Ebolavirus genus is responsible for the infection. The virus is spread through direct contact with the blood or bodily fluids of an Ebola patient who is displaying symptoms or has passed away.

Human-to-human transmission is how EVD spreads throughout the human population, from wild animals to humans. The Ebola virus can cause an acute, severe, and frequently fatal infection if left untreated.

Between two and 21 days after contact with the virus, symptoms typically appear. The disease causes weakness, muscle pain, stomach pain, headache, fever, diarrhoea, vomiting, a sore throat, and bruising, haemorrhage, and unexplained bleeding.

The mechanism of action of Ebanga The recombinant human monoclonal antibody Ebanga (ansuvimab-zykl) is effective against the Zaire ebolavirus. It is made in Chinese hamster ovary (CHO) cells using recombinant DNA technology.

The drug prevents the Ebola virus from attaching to and entering host cells by binding to a glycoprotein that is expressed on the virus's surface. By binding to the LEIKKPDGS epitope on the GP1 subunit's receptor-binding site, it prevents the Ebola virus from entering the host cell and prevents the virus from binding to the Niemann-Pick C1 (NPC1) receptor on host cells.

Ebanga clinical trials The FDA approved Ebanga based on the results of the multi-center, open-label, randomized, controlled Pamoja Tulinde Maisha (PALM) clinical trial.

Numerous other international organizations and agencies participated in the PALM trial, which was led by the US National Institutes of Health and the Institut National de Recherche Biomédicale. It was carried out between 2018 and 2019 during an Ebola outbreak in the DRC.

In adults and children with confirmed Zaire ebolavirus infection, the trial looked at Ebanga's safety and effectiveness. Ebanga intravenously as a single infusion or an investigational control was randomly assigned to the patients.

A single intravenous dose of 50 mg/kg Ebanga was administered to 174 participants in the study, while an investigational control was administered to 168 participants.

The mortality rate on day 28 was the primary efficacy endpoint in the PALM trial. 35.1% of patients who received Ebanga died after 28 days, compared to 49.4% of patients in the control group, according to the findings.

During the clinical trial, patients frequently reported experiencing rapid heart rate, fever, rapid breathing, chills, hypotension, vomiting, and diarrhea. The treatment should not be used in conjunction with a live Ebola virus vaccine, according to the FDA.

#Ebolavirus Infections Drugs Development Market

0 notes

kenresearchcompany · 2 years

Text

Global E Coli Testing Market: Ken Research

Buy Now

Escherichia coli (E. coli) testing denotes to the procedure of detecting and monitoring the existence of foodborne pathogens. E. Coli bacteria is primarily found in contaminated food and water, cheese produced from raw milk, undercooked products, unpasteurized milk and raw fruits and vegetables. It can cause several diseases, such as food poisoning, pneumonia and urinary tract infections (UTIs). Some of the clinical testing approaches for the detection of E. Coli entail enzyme immunoassays (EIA) and polymerase chain reaction (PCR) tests, along with environmental testing approaches, such as enzyme-substrate, membrane filtration and multiple tube fermentation (MTF). These approaches aid in obtaining a precise and quantitative measure of total coliform and bacteria present in the sample.

According to the report analysis, ‘Global E Coli Testing Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)’ states that Alere, InstantLabs, Meridian Bioscience, Accugen Laboratories, Bio-Rad Laboratories, Enzo Life Sciences, Luminex Corporation, Romer Labs, EIKEN CHEMICAL, Becton, QIAGEN, BioMerieux, Diasorin, Pro-Lab Diagnostics, Vivione Biosciences, Nanosphere, Mobidiag and many more are the foremost companies which presently working in the global E Coli Testing market more proficiently for keep maintaining the governing position, registering the great value of market share, leading the highest market growth, ruling the around the globe, generating the highest percentage of revenue and obtaining the competitive edge by establishing the several research and development programs, implementing the policies of profit making and strategies of expansion, improving the qualitative and quantitative measures of such, increasing the features and benefits of E Coli testing, spreading the awareness connected to the applications and advantages of Global E Coli Testing Market, delivering the better customer satisfaction, decreasing the associated prices of such, and analysing the strategies and policies of government as well as contenders.

The effective growth in prevalence of water-borne diseases, such as diarrhea and hemolytic uremic syndrome (HUS), along with the increasing need for clean potable water around the globe, is one of the foremost factors generating a positive outlook for the market. E. Coli tests can help in monitoring the quality of surface and drinking water to safeguard the spread of illnesses and diseases. Not only has this, the widespread implementation of the enzyme-substrate test as an existence or absence (P/A) test is also propelling the market growth. These tests are easy to function, do not demand the sophisticated laboratory equipment and usage of hydrolyzable fluorogenic substrates to detect the existence of several enzymes introduced by the bacteria.

Request for Sample Report @ https://www.kenresearch.com/sample-report.php?Frmdetails=MzQzOTky

Additionally, countless technological innovations, such as the development of innovative bacterial diagnostic instruments and water testing approaches, are underwriting to the market growth. Other aspects, including growing health consciousness among the masses, along with extensive research and development (R&D) activities in the field of microbiology, are predicted to propel the market further. Therefore, it is predicted that during the near period the market of E Coli testing will augment more proficiently around the globe over the review duration.

For more information on the research report, refer to below link:-

Global E Coli Testing Market

Related Reports:-

Global Long-Term Care Insurance Market

Global Raloxifene Hydrochloride Market

LinkedIn | Facebook | Twitter | YouTube

Ken Research

Ankur Gupta, Head Marketing & Communications

[email protected]

+91-9015378249

0 notes

enchantingvoid · 2 years

Text

Molecular Diagnostics Market Analysis, Opportunity and Forecast 2020 to 2030

Global Molecular Diagnostics Market: Snapshot

Rising demand for molecular diagnostics solutions and technologies from industries such as in vitro diagnostics, personalized medicine, research and treatment of a variety of diseases has allowed a vast rise in growth opportunities for the global molecular diagnostics market in the past few years. Molecular diagnostics has led to advances in medical research and treatment of a number of diseases and continues to one of the leading enablers of innovative, accurate, highly sensitive, quick, and economic diagnosis of several diseases. These benefits of molecular diagnostics continue to drive the market.

Download PDF Brochure: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1886

Geographically, North America leads the global market of molecular diagnostics and is expected to dominate with a large share in the revenue pie of the global market throughout the report’s forecast period. In Asia Pacific, which has emerged as one of the most promising markets for molecular diagnostics owing to the rising patient pool of chronic diseases and an improving healthcare infrastructure in emerging economies, India, Japan, and China are expected to present considerable growth opportunities.

Remarkable expansion in diagnostic tests for infectious and genetic diseases is an excellent growth opportunity for the global molecular diagnostics market. In terms of technology, the segment of biochips/microarrays has reported the fastest growth pace over the report’s review period and is expected to expand favorably through the report’s forecast period. The report offers key insights about molecular diagnostics along with a detailed analysis of the factors affecting the growth of this market. Qualitative and quantitative insights on this market have also been presented through this research report.

Global Molecular Diagnostics Market: Overview

Molecular diagnostics refers to a collection of techniques used to analyze biological markers in the individual’s genetic code. The technique is used in diagnosing and monitoring diseases, detecting risks, and deciding suitable therapies for individual patients. It finds applications in blood screening, oncology, microbiology, and genetic tests. The technologies commonly employed in this technique are polymerase chain reaction (PCR), hybridization, isothermal nucleic acid amplification technology (INAAT), and DNA sequencing and next-generation sequencing. Some of the products and services used in the technique are instruments, reagents and kits, and software and services.

Global Molecular Diagnostics Market: Key Trends

The transformative and dynamic nature of molecular diagnostics has facilitated it in evolving as an attractive segment in the global in vitro diagnostics (IVD) industry. It has paved way for advancements in medical research and treatment of numerous diseases. The global demand for molecular diagnostics methodologies is largely supplemented by high sensitivity, accuracy, easy workflow, cost-effective testing, and fast turnaround time offered by these testing modalities.

In addition, these merits have created a gateway for personalized medicines, thus providing momentum to the global market. Moreover, the increasing prevalence of various types of cancer and infectious diseases is augmenting the market. Furthermore, reforms in the U.S. reimbursement scenario are working in favor of the overall market. However, delays in approvals of new molecular diagnostic tests due to the complex regulatory framework are limiting the market from realizing its full potential.

Global Molecular Diagnostics Market: Market Potential

Acquisitions and partnerships have emerged as a common trend in the global molecular diagnostics market over the past few years and are anticipated to continue in the coming years as well. For instance, in September 2016, Danaher acquired molecular diagnostics firm Cepheid for approximately US$4 bn. Another case in point is Qiagen N.V., which in July 2015 collaborated with multiplex clinical molecular diagnostics and multiplex molecular technologies developer Seegene Inc. Such deals are likely to make way for the development of novel diagnostics, which will not only help players in broadening their product offerings but also in making the future of the overall market bright.

Global Molecular Diagnostics Market: Geographical Segmentation

In terms of geography, the report presents an analysis of the market in North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America will represent a large share in the market throughout the forecast period. The growth of the region can be attributed to the presence of well-established and advanced laboratory accreditation infrastructure, government initiatives promoting PoC facilities and awareness regarding the benefits of early diagnosis, and the increasing expenditure on healthcare.

Asia Pacific is expected to register a significant CAGR during the same period, with emerging countries such as India and China being the sights of high growth. The improving healthcare infrastructure, high unmet needs, and growing geriatric populations are attracting global players to invest in the region. The increasing external funding for clinical studies is likely to drive the growth of the region.

Global Molecular Diagnostics Market: Competitive Landscape

A raft of players in the global molecular diagnostics market is entering into strategic partnerships with biotech firms to provide novel diagnostics solutions in order to enhance their visibility. Companies are investing hefty funds in research and development activities to introduce cost-effective and innovative products that will help them in expanding their product portfolio. Several participants are focusing towards business expansion through mergers and acquisitions, which is likely to intensify the competition in the market in the near future.

Some of the prominent companies operating in the market are Abbott Molecular, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services Inc., Bio-Rad Laboratories, Inc., Alere Inc., Dako, Siemens Healthcare, Novartis AG, Becton, Dickinson and Company, Bayer AG, Danaher Corporation, Hologic, Inc. (Gen Probe), and Qiagen.

Key questions answered in this report

What are the diverse growth parameters influencing the market?

Which regions will contribute largely to the growth of the market

What are the recent innovations and technological advancements in the market?

What are the emerging trends across the market?

How has COVID-19 affected the market?

What will be the post-pandemic scenario of the market?

What are the major threats that will dent the growth prospects of the market?

For Full TOC:

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1886

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Rohit Bhisey

Head Internet Marketing

Tel: +1-415-520-1050

Website: https://www.tmrresearch.com/

0 notes

vprprajakta · 2 years

Text

Theranostics Market Analysis | Size, Share, Global Demand and Industry Forecast 2027

Market Overview

The overall theranostics market is driven by progress of innovative companion expressive tests. These components have helped shape the theranostics market and should uphold the turn of events. Associations in the theranostics market could in like manner stand up to challenges like shortfall of fittingly portrayed rules and lacking reimbursement workplaces. The nuances covered in the theranostics market report cover all of the pieces of the business. theranostics market examiners have also shared improvement projections in the report and have proposed theranostics market players to similarly design advancement techniques.

Market Segmentation

The overall theranostics market Has been isolated considering helpful district, advancement, and end-clients. In view of supportive district, the market for theranostics is divided considering cardiovascular diseases, immunological issues, neurological issues, oncology, and others. Additionally, the market in view of advancement, is partitioned into immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, polymerase chain reaction (PCR). The overall market for theranostics is moreover canvassed considering the end-clients segment which is also separated into indicative exploration places, clinical centers and offices, and others.

Factors like increasing paces of diligent ailments and rise in the geriatric people support the theranostics market turn of events. The introduction of theranostics market has moreover been perused up for the past and current years. Additionally, the theranostics market report gives assessment of these bits. The theranostics market segmental examination gave in the report offers huge bits of knowledge concerning the theranostics market show and future.

Key Players

Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Hoffmann-La Roche Ltd, Focus Diagnostics, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Abbott Laboratories, Myriad Genetics, Inc., Foundation Medicine, Inc., AmeriPath, Inc.

Get More Professional and Technical Industry Insights @ https://valuepropresearch.com/report/theranostics-market-1114/

Regional Overview

Associations in the theranostics market are spread across the world. The theranostics market report gives critical information about regional business areas of North America, Europe, Asia-Pacific (APAC), and the rest of the world. The North American theranostics market has numerous associations across the United States, Canada, and Mexico. Europe has associations in the theranostics market across Germany, France, Spain, Italy, and the United Kingdom. An organized assessment of the theranostics market across India, China, and Japan in the Asia-Pacific area is moreover presented in the report. The theranostics market of the Middle East, Africa, and various regions has also been concentrated by specialists. The commonplace assessment of the theranostics market can be found in the factual reviewing report.

Vicious Landscape

The theranostics market is maintained by growing combinations and acquisitions by undeniable market players. The general population advancement all around the planet and growing solicitation of theranostics market based organizations and things moreover support the market improvement. Nevertheless, the theranostics market improvement can be affected as a result of negative methodologies. The report covers commonly such nuances which will help associations in the theranostics market to invigorate their attractive procedure and further foster their thing portfolio. The theranostics market investigation report similarly gives association profiles of huge associations. The association profiles of various affiliations working in the theranostics market report highlights critical nuances like association size, pay advancement, and nuances of solidifications and acquisitions happening in the theranostics market. New associations and spread out associations can plan their techniques taking into account this data gave in the theranostics market investigation report.

Industry News

Blue Earth Diagnostics Gains induction to Scintomics' Radiohybrid's Clinical Applications Expanded cardiology stage gives a wide association in prostate sickness to decide patient therapy from across scope of clinical benefits. The showing framework on the exhibited driving position of Blue Earth Diagnostics in the successful conspicuous verification and commercialisation of radioisotopes for PET. Theranostic radiopharmaceuticals give possible use across both clinical imaging as well as prostate related treatment for harmful development.

#theranostics market

0 notes

techsciresearch · 3 years

Text

Global Telegenomics Market to be Dominated by North America till 2026 | TechSci Research

Increasing occurrence of chronic diseases and the growing demand for personalized medicine is expected to drive the demand for global telegenomics market for the forecast period.

According to TechSci Research report, “Telegenomics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2016-2026 Segmented By Services (On-Demand Access, Genetic Assessment, Test Ordering, Expert Follow-Up), By Specialities (Cancer Genetics, Cardio Genetics, Proactive Genetics, Reproductive Genetics, Others), By End User (Patients & Their Families, Health Professionals, Health & Pharma Companies, Others) and By Region”, the global telegenomics market is expected to witness a growth of steady CAGR for the forecast period, 2022-2026. Genomics can be defined as the complete information based on the sequencing and analysis of the whole human genome. The growing advancements in precision medicine and genomic research have led to the easy integration of genomic data into clinical practice. The availability of genomic data improves the accuracy of the disease diagnosis and the quality of the healthcare treatment being provided by healthcare professionals.

Market players provide the telegenomics platforms to the patients through the help of high-speed internet connection and allow them to schedule virtual visits with the genetic experts. These experts can deliver counseling, education, and other guidance and can also arrange expert consultations to solve the queries of the patients. Service providers can then provide the patient's personalized plan for each patient based on the results of their particular test and can also recommend the patients about what kind of genetic tests they should order. Experts are also able to provide information about the risk for transmission of specific conditions by reviewing the genomic data and drawing a hereditary tree with the available information. The absence of telegenomics can lead to the absence of informed information decision-making about testing and patients lacking the information can order unnecessary and costly genetic tests resulting in unrequired financial loss of patients.

However, the privacy and data security concerns regarding confidential patient genomic data may restrain the global telegenomics market growth for the forecast period.

Browse XX Figures spread through 110 Pages and an in-depth TOC on "Global Telegenomics Market”.

https://www.techsciresearch.com/report/telegenomics-market/7839.html

Global telegenomics market is segmented into service, specialities, end user, regional distribution, and company. Based on the end user, the market can be divided into patients & their families, health professionals, health & pharma companies, and others. The patients & their families segment is expected to account for major global telegenomics market share for the forecast period, 2022-2026. Counselors identify the patients and the families who are prone to get infected with a genetic condition and can easily interpret information about disorders which can prove crucial for successful treatment of disease.

With the obtained data from genetic data analysis, the disease's inheritance pattern can easily recognize, and the risks of occurrence and reoccurrence of disease can be found which helps the patients to make an informed decision. Based on specialities, the market can be divided into cancer genetics, cardio genetics, proactive genetics, reproductive genetics, and others. The cancer genetics segment is expected to hold a significant market share for the next five years.

The high prevalence of cancer around the globe and the high occurrence of breast cancer due to hereditary reasons is driving the growth of the segment. Telegenomics aids in devising better cancer management strategies and helps in lowering the patient's stress level by providing appropriate information. It provides the patients with a high satisfaction level and is also cost-effective.

Genome Medical, Inc., FDNA Telehealth Services, Inc., Gene Matters LLC, IIF Management Company LLC (Illumina Ventures), InformedDNA, Invitae Corporation are the leading players operating in global telegenomics market. Service providers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several telegenomics service providers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7839

Customers can also request for 10% free customization on this report.

“Telegnomics technology can be crucial for prenatal diagnosis and pharmacogenomics in patients. The occurrence of disorders such as neurofibromatosis type 1, Down's Syndrome, Turner's syndrome, and other disorders can be diagnosed in the parents or relatives and the implications of adverse effects, and the long-term impact of the birth defect information are made available to patients which helps them to make informed decisions. The adoption of telegnomics technology is still at an initial stage and the growing awareness among consumers with high-end investments for technological advancements are expected to propel the global telegenomics market growth till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Telegenomics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2016-2026 Segmented By Services (On-Demand Access, Genetic Assessment, Test Ordering, Expert Follow-Up), By Specialities (Cancer Genetics, Cardio Genetics, Proactive Genetics, Reproductive Genetics, Others), By End User (Patients & Their Families, Health Professionals, Health & Pharma Companies, Others) and By Region” has evaluated the future growth potential of global telegenomics market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of global telegenomics market.

Browse Related Reports:

Global Precision Medicine Market By Products & Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, NGS, Others), By Application (Oncology, Cardiology, Respiratory, Neurology, Immunology, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

Global Molecular Diagnostics Market By Products and Services (Reagents and Kits, Instruments, Services and Software), By Technology (Polymerase Chain Reaction (PCR), Sequencing, In-situ hybridization, Chips and microarrays, Mass spectrometry, Others), By Application (Infectious disease, Oncology testing, Genetic testing, Blood screening, Others), By End User (Hospitals, Academic & Reference Laboratories, Others), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/molecular-diagnostics-market/7463.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Telegenomics Market #Healthcare #Telegenomics Market #Telegenomics Market Size #Biotechnology #Telegenomics Market Forecast

0 notes

techscimarketresearch · 3 years

Text

Global Telegenomics Market to be Dominated by North America till 2026 | TechSci Research

Increasing occurrence of chronic diseases and the growing demand for personalized medicine is expected to drive the demand for global telegenomics market for the forecast period.

However, the privacy and data security concerns regarding confidential patient genomic data may restrain the global telegenomics market growth for the forecast period.

Browse XX Figures spread through 110 Pages and an in-depth TOC on "Global Telegenomics Market”.

https://www.techsciresearch.com/report/telegenomics-market/7839.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7839

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

https://www.techsciresearch.com/report/molecular-diagnostics-market/7463.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Telegenomics Market #Healthcare #Telegenomics Market #Telegenomics Market Size #Telegenomics Market Forecast #Biotechnology #Healthcare Reports

0 notes

marketresearch-articles · 3 years

Text

Acute Lymphoblastic Testing Market trends and outlook 2021-27

The acute lymphoblastic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account for USD 2,638.74 million by 2027 growing at a CAGR of 6.20% in the above-mentioned forecast period. The growth of this market is owing to multiple factors such as the increasing volume of partnerships being formulated between various experts and market leaders of diagnostic testing products.

The growing incidence of the population suffering from acute lymphoblastic leukemia is expected to drive the growth of the acute lymphoblastic testing market, in combination with significant expansion of the healthcare industry specifically the diagnostic innovations segment resulting in advanced product offerings and services by the major manufacturers. These factors will act as highly impactful factors for the market’s growth in the forecast period of 2020 to 2027.

Download Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-lymphoblastic-testing-market

The major players covered in the report are NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Adaptive Biotechnologies, Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, Dr. Lal PathLabs among other players domestic and global. Market Share data is available for global, North America, Europe, Asia-Pacific, Middle East, and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Details TOC https://www.databridgemarketresearch.com/toc/?dbmr=global-acute-lymphoblastic-testing-market

Global Acute Lymphoblastic Testing Market Scope and Market Size

The global acute lymphoblastic testing market is segmented based on leukemia type, product & service, technology, and end-user. The growth among segments helps the users analyze niche pockets of growth and assists them in devising strategies for their businesses and determine your core application areas amongst the differences in specific target markets.

Based on leukemia type, the market is segmented into Philadelphia chromosome, B-cell, T-cell. Philadelphia chromosome segment has been further segmented into positive (PH+) and negative (PH-).

Based on the product & service it covers services and assay kits.

Based on technology, the market has been segmented into PCR (Polymerase Chain Reaction), IHC (Immunohistochemistry), NGS (Next-Generation Sequencing), cytogenetics, and others.

The global acute lymphoblastic testing market has also been segmented based on end-user into clinical laboratories, hospitals, academic & research institutes, and others.

View complete report @ https://www.databridgemarketresearch.com/reports/global-acute-lymphoblastic-testing-market

Customization Available: Global Acute Lymphoblastic Testing Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies we can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Browse related report @ Dermatology Diagnostic Devices Market C-Arms Market

CADASIL treatment market

Candidiasis Therapeutics Market

Cardiac Rehabilitation Market

0 notes

kunal9485 · 3 years

Text

Real-Time Polymerase Chain Reaction (PCR) Market Set to Register Healthy CAGR Forecast to 2027

The Real-Time Polymerase Chain Reaction (PCR) Market Report conveys the clean expounded structure of the Market including every single business-related data of the market at a worldwide level. The total scope of data identified with the Market is acquired through different sources and this got main part of the data is orchestrated, handled, and spoken to by a gathering of authorities through the utilization of various methodological procedures and logical instruments, for example, SWOT analysis to produce an entire arrangement of exchange based examination in regards to the Real-Time Polymerase Chain Reaction (PCR) Market.

Real-time polymerase chain reaction (PCR) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 19.50% in the above mentioned forecast period. The rising usage of biomarker profiling for disease diagnostics has been directly impacting the growth of real-time polymerase chain reaction (PCR) market.

Download Free Sample Copy of the Report to Understand the Structure of the Complete Report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-real-time-polymerase-chain-reaction-pcr-market

Prominent Key Players – Covered in the report:

ABL SA Group, Agilent Technologies, Inc., Abbott, Analytik Jena AG, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Fluidigm Corporation, Lumex Instruments, Primerdesign Ltd, QIAGEN, Eppendorf AG, Takara Bio Inc., Thermo Fisher Scientific, bioMerieux S.A., TOYOBO Co. Ltd., and Vela Diagnostics ….

Highlights of the Report?

The report offers a 360-degree overview of the market and emphasizes significant factors promoting, repelling, challenging, and creating opportunities for the market in the forecast duration. The report also lists the names of key players operating in the market and the strategies adopted by them to earn the lion’s share in the market. It also offers interesting insights into the market, current Real-Time Polymerase Chain Reaction (PCR) market trends, and major industry developments of the market. The report also discusses the table of segmentation in detail and lists the names of the leading segment with its attributed factors. It is available for sale on the company website.

Market Segment by Regions:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Real-Time Polymerase Chain Reaction (PCR) Market is framed with a bunch of Graphical Statistics, Table and Figures, Data Analysis Representation described in detail with a clear goal to target potential company stakeholders. Including Industry Chain Structure strongly gives out the overview of market growth and it becomes easy to project the hurdles and upsurge profit graphs. Coming to the Competitive landscape this Real-Time Polymerase Chain Reaction (PCR) Market report gives out each and every aspect required to size the existing market performance including technological advancements, business overview, positive and negative factors of market position and challenges faced but the market leaders to rank themselves above all. Quality parameters like Real-Time Polymerase Chain Reaction (PCR) sales reach, regional coverage, production price trends, and manufacturing cost structure are also studied to give out a perfect competition outlook.

How Does This Market Insights Help?

Real-Time Polymerase Chain Reaction (PCR) Market share (regional, product, application, end-user) both in terms of volume and revenue along with CAGR

Key factors which are driving this market and restraining its growth

What all challenges manufacturers will face as well as new opportunities and threats faced by them

Learn about the market strategies that are being adopted by your competitors and leading organizations

To gain insightful analyses of the market and have a comprehensive understanding of the “Real-Time Polymerase Chain Reaction (PCR) Market” and its commercial landscape

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-real-time-polymerase-chain-reaction-pcr-market

Major Key Contents Covered in Real-Time Polymerase Chain Reaction (PCR) Market:

Introduction of Real-Time Polymerase Chain Reaction (PCR) with development and status.

Manufacturing Technology of Real-Time Polymerase Chain Reaction (PCR) with analysis and trends.

Analysis of Global Real-Time Polymerase Chain Reaction (PCR) market Key Manufacturers with Company Profile, Product Information, Production Information, and Contact Information.

Analysis of Global Real-Time Polymerase Chain Reaction (PCR) market Capacity, Production, Production Value, Cost and Profit

Analysis Real-Time Polymerase Chain Reaction (PCR) Market with Comparison, Supply, Consumption, and Import and Export.

Real-Time Polymerase Chain Reaction (PCR) market Analysis with Market Status and Market Competition by Companies and Countries.

Market Forecast of Global Real-Time Polymerase Chain Reaction (PCR) Market with Cost, Profit, Market Shares, Supply, Demands, Import and Export.

Trending factors influencing the market shares of APAC, Europe, North America, and ROW?

Real-Time Polymerase Chain Reaction (PCR) Market Analysis of Industry Chain Structure, Upstream Raw Materials, Downstream Industry.

Reasons to Purchase this Report

Current and future of global Real-Time Polymerase Chain Reaction (PCR) market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds the highest CAGR in the forecast period

Regions that are expected to witness the fastest growth rates during the forecast period

The latest development, market shares and strategies that are working by the major market players

A complete value chain of the global Real-Time Polymerase Chain Reaction (PCR) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Real-Time Polymerase Chain Reaction (PCR) Market. The market is split on the basis of the categories of products and client application segments. The market analysis demonstrates the expansion of each segment of the global Real-Time Polymerase Chain Reaction (PCR) market. The research report assists the user in taking a decisive step on the way to be a milestone in growing and expanding their organizations inside the worldwide Real-Time Polymerase Chain Reaction (PCR) market.

Some of the Major Highlights of TOC cover:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Real-Time Polymerase Chain Reaction (PCR) Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Real-Time Polymerase Chain Reaction (PCR) Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

In conclusion, the Real-Time Polymerase Chain Reaction (PCR) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-real-time-polymerase-chain-reaction-pcr-market

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rates

0 notes

96thdayofrage · 3 years

Text

The “Killer Vaccine” Worldwide. 7.9 Billion People

The Covid-19 Vaccine should be Halted and Discontinued Immediately Worldwide

“Killer Virus” or “Killer Vaccine”?

The first question which stands out is: Do We Need a Vaccine?

The answer is NO! There is no scientific basis whatsoever which justifies the gene-edited vaccine as a means to saving lives and protecting people’s health Worldwide.

The alleged “scientific justification” for the vaccination program relies on the three simple and misleading “phrases” or “labels” which are totally invalid:

SARS-COV-2 is a “killer virus”

There is a rising Worldwide trend of covid-19 infection,

People are dying as a result of the covid-19 infection.

1. SARS-CoV-2 is “a killer virus”.

That’s the cornerstone of the 24/7 fear and media disinformation campaign upheld by persistent statements by politicians and national health authorities.

Both the peer-reviewed as well the WHO, CDC “official” definitions of SARS-CoV-2 say exactly the opposite. Their definitions of SARS-2 repeal their own lies. (For details see Appendix)

2. There is a Rising Worldwide Trend of Covid-19 infection.

This alleged trend is said to be corroborated by a rapidly increasing number of covid positive cases.

The methodology used to generate these figures is dependent upon the WHO sponsored Real Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) test, the estimates of which are tabulated Worldwide by the national health authorities.

While the estimates of the rRT-PCR have been questioned from the very outset, it is now confirmed by the WHO in a January 20, 2021 advisory that the rRT-PCR test adopted as a means to detecting the SARS-COV-2 virus cases is TOTALLY invalid. (This pertains to Covid positive data tabulated since late January 2020). (See Appendix)

3. People are Dying as a Result of the Covid-19 Infection.

We are told that there is a rising trend of Covid-19 mortality. Namely deaths which are allegedly the result of the SARS-2 viral infection.

There is ample evidence that these Covid-19 related probable causes of death and the underlying data on Covid-19 mortality are manipulated by the national health authorities. Tests, autopsies and postmortems are not conducted. The mortality statistics pertaining to Covid-19 are TOTALLY invalid. (see Appendix which focusses on the US covid related mortality data )

In summary,

1. there is no killer virus,

2. the measurement of covid positive cases is invalid,

3. the Covid-19 mortality data are manipulated.

All of these statements are amply documented. For details see Appendix to this article below.

I should mention that the so-called “emergency use” clause to justify an experimental and unapproved vaccine is also invalid. Why? Because the emergency use criterion relies on erroneous estimates of the rRT-PCR covid positive cases (fake) and Covid-19 related mortality data, both of which are invalid. (See Appendix)

The Vaccine. Hidden Agenda?

The vaccine does not save lives nor does it contain the pandemic, because there is no pandemic. It’s a money-making operation for Big Pharma in the hundreds of billions of dollars (see data below).

Moreover, it’s not a one time vaccine jab. Several doses are contemplated. It is slated to extend over a period of at least two years.

It is applied Worldwide without exceptions. Not a single country with the exception of Burundi, Tanzania and Haiti had the courage to refuse the “killer vaccine”.

While there is no reliable evidence, it is worth noting that the presidents of Tanzania and Burundi died under mysterious circumstances.

Haiti was until recently the only country in the Western Hemisphere which refused categorically to implementing the mRNA vaccine. In a bitter irony, immediately following president Jovenel Moise’s assassination (July 7, 2021), president Joe Biden promptly sent half a million vaccine doses (and more to come) (courtesy of Uncle Sam) which were delivered by COVAX to Port au Prince six days later on July 14.

This first shipment to Haiti was part of a US Aid program consisting of 500 million doses of the “killer vaccine” which is slated to be sent to a large number of developing countries (For further details see below).

Mortality and Morbidity: While there is no “Killer Virus”, there is a “Killer Vaccine”.

The evidence is overwhelming. At the time of writing, almost 20,000 Covid vaccine deaths have been recorded in the European Union (July 17, 2021). In the US the number of registered vaccine related deaths is of the order of 12,000 (July 9, 2021).

According to the EudraVigilance database (July 17, 2021) there were 18,928 deaths and 1,823,219 injuries reported following injections of four experimental COVID-19 shots.

COVID-19 MRNA VACCINE MODERNA (CX-024414)

COVID-19 MRNA VACCINE PFIZER-BIONTECH

COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)

COVID-19 VACCINE JANSSEN (AD26.COV2.S)

From the total of injuries recorded in the EU, “half of them (904,609) are serious injuries“. According to EuroViligance (quoted by by Brian Shilhavy):

“Seriousness … can be classified as ‘serious’ if it corresponds to a medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.”

These are official statistics based on a formal process of registration of deaths and “adverse effects”. The actual number of deaths and injuries triggered by the mRNA vaccine are much higher. Less than ten percent of the victims or families of the deceased will go through the tedious process of reporting vaccine related deaths and injuries to the national health authorities.

According to the latest “official” figures for the EU, Britain and the US (combined), there are 31,389 Covid-19 vaccine related deaths and almost 5 million injuries.

EU/EEA/Switzerland to 17 July 2021 – 18,928 Covid-19 injection related deaths and over 1.8 million injuries, per EudraVigilance Database.

UK to 7 July 2021 -1,470 Covid-19 injection related deaths and over 1 million injuries, per MHRA Yellow Card Scheme.

USA to 9 July 2021 – 10,991 Covid-19 injection related deaths and over 2 million injuries, per VAERS database.

TOTAL for EU/UK/USA – 31,389 Covid-19 injection related deaths and almost 5 million injuries reported so far in July 2021.

Hidden Injuries: The Microscopic Blood Clots

The persons vaccinated will not be immediately aware of the injuries incurred. The latter in most cases are not discernible, nor are they recorded. While “Big Blood Clots” resulting from the vaccine are revealed and reported by those vaccinated, an important study by Canada’s Dr. Charles Hoffe, suggests (yet to be fully confirmed) that the mRNA vaccine generates “microscopic blood clots”.

“The blood clots we hear about which the media claim are very rare are the big blood clots which are the ones that cause strokes and show up on CT scans, MRI, etc.

The clots I’m talking about are microscopic and too small to find on any scan. They can thus only be detected using the D-dimer test.”

“These people have no idea they are even having these microscopic blood clots. The most alarming part of this is that there are some parts of the body like the brain, spinal cord, heart and lungs which cannot re-generate. When those tissues are damaged by blood clots they are permanently damaged.

“These shots are causing huge damage and the worst is yet to come.”

Big Pharma. Pfizer’s Near Global Monopoly

Hundreds of billions of dollars are at stake. This is the largest and most expensive vaccine project in World history which is slated to be financed by tax dollars Worldwide, putting an obvious strain on the public debt of numerous countries.

The vaccine program is accompanied by a “timeline” consisting of recurrent mRNA inoculations over “the next two years and beyond”. As documented above, it will have devastating impacts on mortality and morbidity Worldwide.

What is at stake is a multi-billion dollar Big Money operation for Big Pharma with Pfizer in the lead.

Pfizer-BioNTech (allied with Moderna Inc) is in the process of consolidating its Worldwide (near monopoly) position by pushing out its major competitors including AstraZenaka and Johnson and Johnson (J & J).

Pfizer has been pressuring politicians to endorse their mRNA vaccine. It’s political lobbying is also directed against its Big Pharma competitors. According to Bureau Investigates report:

One official who was present in the unnamed country’s negotiations described Pfizer’s demands as “high-level bullying” and said the government felt like it was being “held to ransom” in order to access life-saving vaccines.

Ironically, in the EU, the reported deaths and injuries were used by the European Commission to cancel the renewal of the contract with AstraZeneka, despite the fact that there were substantially more deaths and injuries associated with the Pfizer-BioNTech vaccine.

In April 2021, the EU Commission confirmed that it would “end AstraZeneca and J&J vaccine contracts at expiry”. “The Pfizer shot will take precedence”. Never mind your followup dose with AstraZeneka, the health authorities have instructed people to get their second or third jab with Pfizer or Moderna (thereby visibly violating medical norms).

Having sidelined its competitors, Pfizer-BioNTech has jacked up the price of the vaccine vial. Pfizer has literally cornered both the EU and US markets. A near global vaccine monopoly is in the making.

The European Union

In mid-April 2021 the President of the European Commission confirmed that Brussels is in process of negotiating a contract with Pfizer for the production of 1.8 billion mRNA vaccine doses, which represents 23 percent of the World’s population.

That’s exactly four times the population of the 27 member states of the European Union (448 Million, 2021 data), which confirms that several followup doses of the “killer vaccine” are envisaged, despite the trend in mortality and morbidity which the governments and the media are attempting to suppress as part of a hideous disinformation campaign.

Pfizer and the US Market

A similar pattern is occurring in the US and Canada. In July 2020, Pfizer signed a $1.95 billion contract with the U.S. government for 100 million doses. And then in December 2020 another 100 million doses were delivered.

In Canada, another 35 million doses of Pfizer and Moderna vaccine vials are slated to be delivered.

And now July 2021 the Biden administration has ordered 200 million more doses of the Pfizer vaccine. “for children’s shots and possible boosters”

But that’s not all: in early June 2021, Biden ordered 500 million Pfizer-BionTech doses of the “killer virus” to be sent as “US Aid” to developing countries (courtesy of Uncle Sam).

In most Western countries including the US and Canada, the retail price of the vaccine is “Free”.

In the US, a total of 900 million doses of Pfizer-BionTech vaccine vials is Big Money for Big Pharma: Massive profits for Pfizer, all of which are slated to be financed by tax revenues coupled with a dramatic expansion of the US public debt.

In the first quarter of 2021 (January through March 2021), the gross revenues accruing to Pfizer and Moderna were as follows:

#1. Pfizer-BioNTech COVID-19 vaccine. U.S. sales were $2.038 billion; global sales were $5.833 billion.

#2. Moderna COVID-19 vaccine. U.S. sales, $1.358 billion; global sales, $1.733 billion.

Recently announced (23 July 2021), Pfizer has jacked up the price of its vaccine vial from $19.50 to $28.00.

Multiply $28.00 by three vaccine doses per person for a World population of 7.9 billion, What do you get?

This is not an estimate, it’s an “order of magnitude”: 663.6 billion dollars ($28.00 x 3 x 7.9 billion = $663.6 billion).

It is all for a good cause: save lives?

We are talking about a multi-billion dollar operation at tax payers expense, which has resulted in a pattern of vaccine related deaths and injuries. And the governments are fully aware of what is happening.

Pfizer’s Criminal Record

Is Pfizer “a reliable partner” as claimed by the EU Commission President van der Leyen?

A global vaccine monopoly is unfolding controlled by a company which has a criminal record (2009) with the US Department of Justice.

It was not the routine civil class action law suit waged against the pharmaceutical industry. It was a criminal indictment for “fraudulent marketing”. While there were no arrests, Pfizer was so to speak “Put on Parole” under a US DOJ indictment.

In a historic US Department of Justice decision in September 2009, Pfizer Inc. pleaded guilty to criminal charges. It was “The Largest Health Care Fraud Settlement” in the History of the U.S. Department of Justice.

Pfizer to Acquire A Near Monopoly of the Global Covid Vaccine Market

And now among all major Big Pharma actors, it’s a company with a criminal record which has established a de facto near monopoly at a World Level.

Can we trust a Big Pharma vaccine conglomerate which pleaded guilty to criminal charges by the US Department of Justice (DoJ) including “fraudulent marketing” and “felony violation of the Food, Drug and Cosmetic Act”?

‘Fraudulent marketing” in the case of the Pfizer-BioNTech’s “killer vaccine” is a gross understatement. What is Value of Human Life? It does not have a monetary value.

Can we trust the politicians in high office who granted these multibillion Euro/dollar contracts to Pfizer, which are funded by tax revenues.

Is this a “mistake” on the part of the national health authorities? The experimental mRNA “vaccine” has resulted in an upward trend in mortality and morbidity Worldwide. Meanwhile, Big Pharma profits are in the hundreds of billions.

And governments, acting on behalf of Big Pharma are pressuring people to get vaccinated to no avail imposing penalties to those who refuse.

National health authorities claim that the Covid-19 “vaccine” will save lives. That’s a lie.

Do we Know What’s inside the Pfizer Vaccine Vial?

The causes of vaccine related deaths and injuries have not been addressed by the health authorities.

What is inside the vaccine vial? National health authorities have not made public the results of their lab exams. It is unclear as to whether those lab exams of the vaccine vials have been conducted.

Below is a review of the analysis and laboratory research conducted by the independent Quinta Columna Spanish team.

Graphene Oxide Nano-particules

According to lab exams conducted by the Spanish Quinta Columna research team, graphene oxide nano-particles have been detected in the vial of the Pfizer mRNA vaccine.

The results of their research (analysis by electron microscopy and spectroscopy) are far-reaching. Graphene oxide is a toxin which triggers thrombi and blood coagulation. It also has an impact on the immune system. Graphene oxide accumulated in the lungs can have devastating impacts.

0 notes

ijcmcrjournal · 3 years

Text

Assessment of Interference Approaches in Response to COVID-19 Outbreak by Khurshied AK* in IJCMCR

Abstract

The start of (2020) is underway with the rise of novel coronavirus known as SARS –CoV-2 that triggering pneumonia-related respiratory syndrome all over the world. It is the third intensive pathogenic and contagious coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) appeared in humans. The cause of beginning, diffusion to humans and contrivances linked with the pathogenicity of SARS-CoV-2 are not vibrant yet, however, its similarity with SARS-CoV and numerous other bat coronaviruses was newly established and concluded through genome sequencing interrelated studies. The progress of therapeutic strategies is required in order to inhibit further epidemics and cure disease-ridden people. In this Review, we summarize existing data about the development, source, diversity, and epidemiology of three pathogenic coronaviruses with a detailed attention on the present outburst in Wuhan, China. Additionally, we discuss the clinical features and potential therapeutic possibilities that may be effective counter to SARS CoV-2.

Keywords: Novel coronavirus; Outbreak; Therapeutics

Introduction

The episode of coronavirus infection 2019 (COVID-19) gears in Wuhan city, Hubei province of China initially developed in December 2019. Recently known unique coronavirus (SARS-CoV- 2, earlier known as 2019-nCoV) is affecting pneumonia related respiratory syndrome [1]. Subsequently investigation of genome classifications of SARS-CoV-2 samples collected from various disease-ridden patients, SARS-CoV-2 bonds strong sequence uniqueness with SARS- CoV [2]. At mid of April 2020, about 209 countries reported >1.9 million cases of SARSCoV-2 infection. Patients diseased with SARS-CoV-2 showed confirmation of common pneumonia with serious lung damage [3]. COVID-19 could be distinguished by clinical CT radiography or a laboratory real time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) [4].

Unluckily, there is no particular antiviral drug or vaccine now a days. Some options can be used to switch infections of SARS-CoV-2, including vaccines, antibodies, inhibitory mechanism and small molecules drugs [5]. The antibody reaction is a key for averting viral infections. A subclass of these antibodies, which condense viral infection by adhesion to the epitopic area of viral fragments and thereby hindering the access of the virus to an infected cell, are defined as negating antibodies (NAbs) [6]. This review concentrates on understanding immuno- pathogenesis of SARS-CoV-2 and discussing the advances, challenges and studies of neutralizing antibodies (NAbs).

Diversity and Source of Extremely Pathogenic Coronaviruses

Diverse strains of MERS -CoV reported from camels were establish parallel to those isolated from humans [7], excluding, genomic dissimilarities among S, ORF4b and ORF3 regions [8]. Moreover, genome sequencing -established studies exposed that MERS -CoV s from humans are phylogenetically correlated to those form bats. They have undistinguishable genomic and protein assemblies excepting for the S proteins [9]. In addition recombination s analysis of genes encoding orf1ab and S shown that MERS -CoV patented from the give-and-take of genetic components between coronaviruses in camels and bats (10). While the zoonotic origion of SARS

-CoV-2 is not proved, its genome sequence revealed adjacent affinity (88% identity) with two bat -resultant SARS -like coronaviruses (bat - 89 SL -CoVZC45 and bat -SL-CoVZXC21). Phylogenetic examination discovered that SARS -CoV-2 was genetically distinctive from SARS

-CoV and MERS -CoV. However, homology exhibiting shown that both SARS -CoV and SARS

-CoV-2 had analogous receptor-binding sphere structures, despite amino acid disparity at some crucial remains. Such as the absence of 8a-proteinand non-stable number of amino acids in 8b and 3c-proteins in SARS -CoV2. In contrast, the core protease is extremely well-maintained among SARS -CoV-2 and SARS -CoV with a 96% complete uniqueness. These remarks advocate that bats are the foundation of source, whereas an animal retailed in the Wuhan seafood market strengthen a transitional cloud aiding the beginning of the virus in humans [10].

Clinical features connected with patients affected with SARS -CoV, MERS -CoV and SARS - CoV-2 ranging from a slight respirational epidemic to serious critical respiratory illness. Both MERS and SARS patients in later phases mature respiratory suffering and renal letdown. Pneumonia appears to be the record and repeated index of SARS -CoV-2 infection, considered mainly by fever, cough, dyspnea, and related infiltrates on chest imaging. The period from infection to appearance of symptoms differs. Commonly, it is supposed to be 14 days, but, a study group at Guangzhou Medical University stated the maturation period to be 24 days. In a local cluster of groups and joint families the infections start of fever and respiratory illness signs transpired about three to six days after possible contact [11].

Therapeutic Possibilities for Human Coronaviruses

Presently no favorable antiviral cure existing, however, frequent compounds have been established active against SARS -CoV and MERS -CoV but not verified extensively for recently appeared SARS -CoV – 2.

Development of Neutralizing Antibodies to 2019-Ncov

Coronavirus access rises with the S protein binding to a destination receptor on the cell surface, where after merging is facilitated at the cell membrane, providing the viral nucleocapsid into the cell for consecutive duplication [12]. The S protein is well-known for triggering syncytial development into diseased cells and receptor-contaimimg cells around them, highlighting that the S proteins are not only functional inthe virion state.

A neutralizing antibody aiming the S protein on the surface of 2019-nCoV is possibly the first therapy expected by biomedical investigators in academics and industry, serve as an inert protection to illness [13]. The newly available genome sequence of 2019-nCoV (GenBank: MN908947.3) permits scientists to triumph gene fusion in the lab and reflect stating the S protein as an immunogen. Conventional approaches of screening mice or rabbits for neutralizing antibodies may be quite paasive for this outbreak, but quick methods such as, super computer that express antibody fragments could be used to classify prime competitor for viral neutralization [14].

The problem is that some antibody aspirant would be carefully deep-rooted in cell culture and animal models to endorse that it can neutralize 2019-nCoV and avert epidemic. Evidence from other coronaviruses types such as SARS could be supportive to target the best epitope in order to create neutralizing antibodies (the receptor-binding area in the S protein is a significant target) [15], but again this is a time cosuming and thought-provoking procedure, which might not return substantial advances for some months. Furthermore, finally a combination of antibodies might be vital to safeguard full defense for long suffering patients, which could enhance supplementary complication for preparation and production.

A substitute approach of creating counterbalancing antibodies contrary to 2019-nCoV S protein could develop immunity in large animals (sheep, goat, and cow) with the 2019-nCoV S protein, and then liberating and cleaning the polyclonal antibodies from the animals [16].This approach may assist an accelerated facility in the background of an epidemic and has several leads such as streamlining assembly and built-up, but has partial assurances that every animal could create neutralizing antisera, or the antibody titer present in each animal [17]. In addition, the human immune reaction’s counter to foreign immuno-globulins to other species, which could hypothetically confuse any cure developments [18]. In a really anxious situation, this approach may be practical for a precise range, but not balanced in the 2019-nCoV epidemic, that is promptly proliferating currently [19].

Perceptions on the Progress of Neutralizing Antibodies against SARS-Cov-2

To practice the Plasma transfusion of recovered patients in the infected patients would be an alternative approach during the outbreak, due to presence of Polyclonal Nabs. [20]. These Polyclonal NAbs could be active and effective in in handling SARS-CoV-2 if induced properly [21]. Further these NAbs can deal with inactive immune responses to viral infection in the patients. Actually Convalescent plasma therapy was successfully applied to SARS and Ebola infected patients in past and established and marked as curing therapy but the problem and challenges during this therapy are irregularity inert plasma and inconsistency of sera in different patients [23]. To make the therapeutic antibodies successful antibody-antigen computational model can developed to monitor the strategy [24]. The Protein Data Bank (PDB) Sstatistics shown that about (presently about 2,000 testimonies) of antibody configurations are accessible. Though Assembled data base of these PDB statistics, the comparative specific characteristic of antibody against viral inefection can be projected. The significant developmet and advancement in NAbs can be documented to can make available profile for researcher will be key for the vaccines counter to SARS-CoV-2. The crucial residues of boundary between an antibody and the antigen can be improved to yield in elevation affinity [25]. Numerous current computer cropping models have been used to guess the interface between S protein and human ACE2 [21] or antibodies [26]. The studies Int. J. Biol. Sci. 2020, Vol. 16 http://www.ijbs.com 1722 exposed the significant finding that SARS-CoVspecific CR3022 antibody could cross-react to SARSCoV-2.

Via Oligonucleotides against 2019-Ncov RNA Genome

Via Oligonucleotides against 2019-Ncov RNA Genome In addition to targeting the extracellular proteins of 2019- nCoV, the RNA genome itself can be targeted to be dispersed. The recently identified published 2019-nCoV genome sequence (GenBank: MN908947.3) could be consider another strategy Then, is it the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASO) to fight the virus targeting its RNA genome [27]. The first problem with this strategy is unknown sequence of RNA domain of Cov-2109 Isolating preserved classifications is crucial before in direction to adjust siRNA leveling and reduce viral outflow of the oligonucleotide strategy. The comparative genome homology study of 2019-nCov will be significant to identify conserved sequence .The delivery of oligonucleotides into the lungs would be second big challenge for For this purpose lipid nanoparticles can be effective delivery vehicle to the lungs [28]. It is still unclear how much siRNA’s or ASO’s delivered within the lungs would be effective to stop the infection. For example, if lungs had siRNA or ASO 25% of alveolar epithelial cells that competence strength be a pronounced achievement over for traditional gene therapy, but would scarcely mark any metamorphosis in an epidemiologic infection [29]. Such siRNA candidates description correspondingly expose in case of failed Ebola trials, while its preclinical success in animal models. [30] Finally, if someone supposed that siRNA was result oriented clinically, but to to a large infected population there is inadequate capacity of SiRNA in manufacturing drug. Existing siRNA and ASO treatments are manufactured for rare diseases, and there are no available resources existing to manufacture the medications quickly [31].

Chemotherapeutic Alternatives for SARS-Cov-2 Infection

To handle the infected patients there is no prescribed clinical drug or vaccine developed or yet permitted by authorities Precautionary and life supporting treatments are presently deliver to infected patients .These prescription and set of established therapies include , antibiotic treatment along with oxygen therapy and further and antifungal treatment, extra-corporeal membrane oxygenation (ECMO) etc. according to symptoms of patients [31]. The seven antiviral drugs on Vero E6 cells in vitro were evaluated by Wang et al against SARS-CoV-2 infection, chloroquine, remdesivir (GS-5734) favipiravir (T-750), penciclovir, nitazoxanide, nafamostat, ribavirin, nitazoxanide, nafamostat [32]. The anti-malaria drug chloroquine and remdesivir were found more effective with low cytotocity as compared other seven drug treatments. The concentration (EC50) for chloroquine and remdesivir were 0.77µM and 1.13µM respectively which showed better improvements in the patients. Chloroquine is found effective in Vero E6 cells at different stages of SARS-CoV-2 infection (viral entry and post-entry stages) whereas s at post –entry satge remdesivir is more ecffetcive.

The antiviral activities of Chloroquine as a drug used for a malarial infection with potential broad-spectrum are established in the past [33]. The previous successful clinical trial indicates that with EC90 (6.90 µM) in Vero E6 cells is clinically achievable against SARS-Cov with significant results [27]. While Remdesivir as a drug presently under consideration which was effective during SARS-CoV and MERS-CoV in the past [34]. Remdesivir improves the functioning adenosine analogue and targeting RdRp, which results in in early expiry of the virus transcription. The most suitable trial of EC90 in Vero E6 cells is 1.76 µM with remdesivir against SARS-CoV-2 in nonhuman primate experiment is achievable [34]. In the United States, it is encouraging to note that treatment with remdesivir against viral infection was recommended to the patient on the day 7 without any adversarial events witnessed. The patient’s clinical symptoms improved on day 8 and the earlier condition wiped out, indicating the remdesivir capacity be effective to the treatment of SARS-CoV-2 infection. However this result should be taken with attention and care as this is only single case study and a proper trial control was lacking [34]. Presently, chloroquine and remdesivir are under phase 3 clinical trial and open- label trial for treatment of SARS-CoV-2 infection respectively. Initial results displayed that chloroquine phosphate had deceptive efficiency in handling of COVID-19. However, consideration required be taken during clinical practice of chloroquine as its overdose is exceptionally terrible without known solution [34].

Conclusion

SARS-CoV-2 is an developing threat and evolving infection, lacking actual treatment and existing drug or vaccine for instant management. The current mortality rate 2.3% of SARS- CoV-2 which is extremely alarming due to large number of infected patients could result in failure of health system of many states within short period of time ,and its strong apprehension that mortality rate might increase with of passage of time if defensive measures not taken in time. In addition, finical assistance is required to research groups to prepare antiviral drug within short span of time. In the meantime, to avoid the epidemic of this and other novel viruses in future. Guideline should be vigorously adopted by states to forbid the trade of uninhabited animals in food staff, because they are conceivable intermediary host(s) of several viruses. During the unexpected existing outbreak to deal with patients, Nabs therapeutic option remains at high significance .In coming couple of months Nabs therapeutic approach and its understanding mechanism may offer potential proposal for speedy progress of antibody therapy and vaccine for SARS-Cov-2.

For more information about Journal :

https://ijclinmedcasereports.com/

https://ijclinmedcasereports.com/pdf/IJCMCR.SC.ID.00013.pdf https://ijclinmedcasereports.com/ijcmcr-sc-id-00013/

#Novel coronavirus #Outbreak #Therapeutics #ijcmcr #clinical studies

0 notes

techsciresearch · 3 years

Text

Product Review: Bio-Rad Laboratories CFX Opus 96 and CFX Opus 384 | TechSci Research

The application of a real-time Polymerase chain reaction (PCR) system in the field of molecular diagnostics has become a standard method for identifying nucleic acids from collected microbial samples. The real-time PCR (also known as RT-PCR) systems are sensitive, rapid, precise, and minimize the risk of contamination while being employed for various research procedures such as detection and expression analysis of genes, quantitative genotyping, early diagnosis of diseases, forensics, etc. Ever since the introduction of RT-PCR, the technology is just getting better with each medical innovation. The COVID-19 pandemic has put RT-PCR in the spotlight as it is considered the most accurate and efficient testing method for the detection of the SARS-CoV-2 virus. The use of RT-PCRs has been tremendously expanding for the testing of novel coronavirus and the demand is likely to grow due to the rising incidences of infectious diseases.

Recently, Bio-Rad Laboratories introduced the next generation of the company's CFX real-time PCR systems, CFX Opus 96 and CFX Opus 384, that offers improved connectivity and high performance. The sleek and modern CFX systems bring forth the next revolution in qPCR with their easy-to-use interface and advanced connectivity options. Both the RT-PCR systems are ideal for basic and translational research, genomic testing, quality control, process development, detecting infectious diseases, as well as pathogen detection. Along with expanding Bio-Rad's portfolio of CFX products, the company also launched cloud-based instrument connectivity and data management system, BR.io.

Consolidating an accurate optical shuttle system and improved thermal performance, the new CFX systems are designed to provide more consistent data than ever. The advanced RT-PCR systems are capable of performing stand-alone operations, which makes them indispensable as life-research tools for diagnostic interventions. The systems show excellent compatibility to ethernet as well as Wi-Fi, and thus enable completely wireless operations and data management. The user can transfer the retrieved data by connecting the CFX systems with a PC or via direct data transfer to a USB device. In network-connected locations, the CFX Opus system can be programmed to send the data as well notifications directly to your email or local drive, and thus the updated systems deliver an efficient experience to RT-PCR users.

Bio-Rad Laboratories' CFX Opus 96 has five color detection formats whereas CFX Opus 384 RT-PCR provides four color detection formats. The sensitive and modern touchscreen of the systems is responsive even with double gloves and more intuitive than previous generation CFX systems. However, the uniform optical system does not have regular calibration requirements, which saves time and effort. Additionally, the products' block design delivers tight thermal uniformity during the real-time PCR experiments.

Shuttle Optics Technology The newly launched CFX Opus systems retain many features of the previous generation models that researchers and scientists liked. Both the systems have been built upon the same proprietary optical design, employed across the company's portfolio of CFX products, however, the latest ones are easy to set up and install due to improved capabilities and flexible connectivity options. The device manufacturer has put efforts in making the design of the CFX system sleek and modernized, for which they have transcended from a clamshell lid to a retracting version, which allows the RT-PCR to be used in even more spaces than before. Despite the design modifications, the updated system looks somewhat familiar to previous systems, but they are more convenient.

The CXR Opus systems incorporate shuttle optics technology that utilizes the same excitation-detector pair just like other systems in the Bio-Rad's RT-PCR portfolio. In the new systems, shuttling the optics across the plate eliminates the possibility of variability that may result from detectors. Besides, the technology reduces the need for correction in detector angle arising from a single fixed camera. The consistency of the device is further augmented with the significant development in thermal performance, which provides uniformity of ±0.3â°C and accuracy of ±0.2â°C. Both the shuttle optics technology and the high-performance thermal gradient work brilliantly together and produce consistent and reliable results.

CFX Maestro Software The CFX systems come with an updated and full-featured CFX Maestro Software, that is easy to use and learn. The software allows users the ability to perform statistical analyses of gene expressions and find solutions to complex biological questions. Also, the user can make an analysis without exporting the retrieved data into a PC with the help of Maestro Software. The software also consists of a Laboratory Information Management System (LIMS) integration, application programming interface (API), and other functions for more advanced users.

BR.io Cloud Platform Bio-Rad Laboratories has expanded the family of life science tools with the addition of the BR.io cloud platform, which provides users a simplified qPCR experience. The cloud connectivity platform incorporates in CRX Opus systems provides a robust solution to meet the needs of the customers in the expanding field of genomics research and diagnostics. Leveraging BR.io, the users can retrieve remote data with any internet-connected computer as well as monitor registered instrument status, thus the cloud connectivity ensures efficiency and provides enhanced versatility in operations. You can connect to the CFX Opus systems to the BR.io cloud platform through an Ethernet connection or with simple Wi-Fi connectivity and access local network file drives for which your institution has granted access. Thus, BR.io provides seamless data transfer, enable users to access data anywhere from the cloud, design experiments, and analyse data.

Latest Additions in RT-PCR systems Azure Cielo 3 Real Time qPCR System Launched in June 2020, the Azure Cielo real-time PCR system is a 96-well qPCR machine dedicated to genomics workflow. The new RT-PCR system delivers a high-performance and provides intuitive workflow due to its innovative optical design. The device assures sensitivity and reproducibility with optimal excitation reaction utilizing single-well excitation and emission. The system features a 10.3" touch screen interface that makes setting up and checking status easy. Data from the compact device can be retrieved via USB, ethernet, or Wi-Fi in a connected environment. The RT-PCR device comes with Azure Cielo Manager software that offers a comprehensive workflow solution and enables accurate analysis. Azure Cielo qPCR is a user-friendly and precise instrument that generates good reproducibility and enhances the productivity of researchers by automating sample extraction, amplification, and detection in one cartridge.

Palm PCR S1 Ahram Biosystem has developed an ultra-fast mobile real-time PCR system that allows one to instantly complete PCR tests anywhere and anytime without any electricity, or communication. A brilliant innovation in RT-PCR systems, the Palm PCR S1 is considered the future of biotechnology. The mobile device is extremely efficient and convenient, which can deliver results in less than 12 minutes with high accuracy even with a single copy target concentration. Powered with convection PCR technology, the ultra-fast system has a maximum of six real-time channels available, thus the full capacity of the device can be achieved without detectable crosstalk. The standalone device consists of a lithium battery that enables four hours of continuous operation and can be operated at temperatures up to 40 degrees Celsius. The device can be easily connected with a PC via Bluetooth and Wi-Fi.

Conclusion Recognizing the importance of molecular diagnostics for the detection of pathogens responsible for infectious diseases, many biotech companies are coming up with innovative RT-PCR systems. Standardization and quality control have remained some of the major limitations of diagnostic PCR, but the new methodologies and technologies are utilizing artificial intelligence to reduce the need for human input. PCR diagnosis is likely to have a huge impact on the customization of healthcare and the development of drugs in the coming years.

According to TechSci Research report on "Global dPCR and qPCR Products Market By Technology (Quantitative, Digital), By Product (Consumables & Reagents, Instruments, Software & Services), By Application (Clinical (Pathogen Testing, Blood Screening, Oncology Testing, Others), Research, Forensic, Others), By End User (Hospitals and Diagnostic Center, Research Laboratories and Academic Institute, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Forensic Laboratories), By Region, Forecast & Opportunities, 2025", the global dPCR and qPCR market is estimated to register a significant CAGR owing to rising incidences of infectious diseases as well as increasing application of biomarker profiling for disease diagnostics. Moreover, introduction of technological advancements in PCR technologies and high costs of advanced PCR devices might hinder the growth of dPCR and qPCR market.

According to another TechSci Research report on "Global Real Time PCR Market By Product (Instruments, Reagents & Consumables, Software & Services), By Application (Clinical (Pathogen Testing, Blood Screening, Oncology Testing), Research, Forensic, Others), By End-user (Hospitals & Diagnostic Labs, Research Laboratories & Academic Institutes, Pharma-Biotech, Clinical Research Organizations (CRO), Forensic Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2025", the global real-time PCR market is expected to grow significantly due to increasing advancements in PCR techniques and introduction of funds and grants by government and healthcare organizations across the globe.

#TechSci #Market Research Reports #Global Real Time PCR Market #Healthcare #Global dPCR and qPCR Products Market #Bio-Rad Laboratories #CFX Opus 384 #CFX Opus 96

0 notes

techscimarketresearch · 3 years

Text

Product Review: Bio-Rad Laboratories CFX Opus 96 and CFX Opus 384 | TechSci Research

#TechSci #Market Research Reports #Global dPCR and qPCR Products Market #Global Real Time PCR Market #Bio-Rad Laboratories #CFX Opus 96 #Healthcare #CFX Opus 384

0 notes

newstfionline · 4 years

Text

Friday, January 1, 2021

Happy New Year!

New Year’s revelries muted by virus as curtain draws on 2020 (AP) This New Year’s Eve is being celebrated like no other in most of the world, with pandemic restrictions limiting crowds and many bidding farewell to a year they’d prefer to forget. As the clock struck midnight across Asia and the South Pacific, the New Year’s experience mirrored countries’ responses to the virus itself. Some canceled or scaled back festivities, while others without active outbreaks were able to carry on like any other year. Australia was among the first to ring in 2021 because of its proximity to the international date line. In past years 1 million people crowded Sydney’s harbor to watch fireworks. This time, most watched on television as authorities urged residents to stay home. In South Korea, Seoul’s city government canceled its annual New Year’s Eve bell-ringing ceremony in the Jongno neighborhood for the first time since the event was first held in 1953, months after the end of the Korean War. The ceremony normally draws an estimated 100,000 people. Cities and countries that have managed to control the virus got to celebrate. New Zealand, which is two hours ahead of Sydney, and several of its South Pacific island neighbors that also have no active COVID-19 cases held their usual New Year’s activities. Taiwan also hosted its usual New Year’s celebration, a fireworks display by its capital city’s iconic Taipei 101 tower. The island has registered only seven deaths and 700 confirmed cases. Much of Japan welcomed 2021 quietly at home, alarmed after Tokyo reported a record daily number of confirmed coronavirus cases, topping 1,000 for the first time. Many skipped a chance to return to ancestral homes for the holidays, hoping to lessen health risks for extended families. In many European countries, authorities warned they were ready to clamp down on revelers who breached public health rules, including nightly curfews in Italy, Turkey, Latvia and the Czech Republic. Many around the world looked toward 2021 with hope. In Israel’s coastal metropolis of Tel Aviv, flower shop owner Billie Heyman reflected on how 2020 taught people to be “more friendly and gentler with each other.” “Because, when we don’t have this, we have nothing,” she said.

COVID-19 shook, rattled and rolled the global economy in 2020 (Reuters) When 2020 dawned, the global economy had just notched its 10th straight year of uninterrupted growth, a streak most economists and government finance officials expected to persist for years ahead in a 21st Century version of the “Roaring ‘20s.” But within two months, a mysterious new virus first detected in China in December 2019—the novel coronavirus—was spreading rapidly worldwide, shattering those expectations and triggering the steepest global recession in generations. The International Monetary Fund estimates the global economy to have shrunk by 4.4% this year compared with a contraction of just 0.1% in 2009, when the world last faced a financial crisis. Government-mandated shutdowns of businesses and any non-essential activities in much of the world unleashed a wave of joblessness not seen since the Great Depression. Still, unemployment levels varied dramatically across the globe. Most economists expect it to take a year or more for labor markets to return to something resembling the pre-pandemic era.

Canada to require negative coronavirus test for air travelers entering country (The Hill) Canada will require air travelers to present a negative COVID-19 test in order to enter the country, officials announced Wednesday. Travelers coming into Canada by plane will have to get a negative polymerase chain reaction (PCR) test within 72 hours of boarding, which Intergovernmental Affairs Minister Dominic LeBlanc said will likely be in place within a week, the Canadian Broadcasting Corporation reported. Canada currently mandates that those who enter the country quarantine for 14 days, which Public Safety Minister Bill Blair said during a press conference would not be affected by the new restrictions. “This is not an alternative to quarantine,” Blair said, according to the CBC. “It’s an additional layer.” Disobedience of the quarantine period could result in up to six months in prison or up to $750,000 in fines.

Virus aid, police reform dominate new US laws for 2021 (AP) Responses to the coronavirus pandemic and police brutality dominated legislative sessions in 2020, leading to scores of new laws that will take effect in the new year. Virus-related laws include those offering help to essential workers, boosting unemployment benefits and requiring time off for sick employees. A resolution in Alabama formally encouraged fist-bumping over handshakes. Legislatures also addressed police use of force against Black people and others of color after the killing of George Floyd in Minneapolis led to widespread protests against police brutality. Among other things, new laws will mandate oversight and reporting, create civilian review panels and require more disclosures about problem officers.

Louisiana residents struggle months after storms (AP) Well after Hurricanes Laura and Delta ravaged southwest Louisiana, the state and its people are still far from recovered, with many living in tents and cooking their meals over open fires while they slowly work to rebuild their destroyed homes. Ricky and Cristin Trahan are among those still struggling, months after Hurricane Laura roared through the region as a Category 4 storm in August, followed by Category 2 Hurricane Delta in October. From a relative’s house where they had taken refuge, the Trahans watched as Laura flipped over and destroyed their mobile home. When they returned, any possessions that hadn’t been looted were strewn about their property. Since then, they have been living as a family in tents, only recently acquiring a camper for their son, Ricky Jr.; his fiancée, Katelyn Smith; and their 1-year-old boy; and a propane water heater that has allowed them to take hot showers. Eventually the Trahans expect to receive a trailer from the Federal Emergency Management Agency, but they don’t believe it will arrive for some time. In the meantime, they do their best to survive in the cold, often rainy nights, improvising as they go along to survive in the rubble that was once their home.

She’s young, has no serious health conditions—and hasn’t left isolation since March (Washington Post) On the 265th day of her isolation, Barbie Furtado woke with a migraine. Outside, millions of people were getting on with the business of their days. Fortaleza, the Brazilian city of 2.6 million where Furtado shares a three-bedroom apartment with her mother and brother, was reporting fewer than 30 daily coronavirus cases. People were back on the streets. Shops and schools were open. Friends and family were urging her to join them. But Furtado, a 32-year-old woman without any serious health conditions, hadn’t been outdoors since March 18. Not even to take a stroll. “I’m not ready to go out,” she said. In Brazil, a country of profound inequality, where delivery services are extremely inexpensive, the comfortable can afford to order in virtually any service or product: groceries, medications, wine. The hairdresser makes house calls. So does the manicurist. Friends send home-cooked meals via mototaxi. Want a coronavirus test? The lab will send over a technician. Brazil’s deliver-anything culture has enabled a minority of people to achieve an extraordinary degree of isolation. In August—six months into the pandemic—surveys showed that 8 percent of Brazilians still hadn’t left their houses. In October, amid the lull between the first and second coronavirus waves, 1 percent of people still weren’t leaving. Now, as cases and deaths rise once more, people are retreating back into complete isolation, or are grateful they never left it. “It’s not just the wealthiest classes,” said Gessuir Pigatto, an economist at São Paulo State University who studies the delivery economy. “It’s all classes. We have the opportunity to always stay home.”

Scores Missing, Hundreds Evacuated After Clay Landslide Strikes Village in Norway (Daily Beast) At least 26 people are unaccounted for and more than 200 people have been evacuated after a massive sheet of clay caused a devastating landslide in the Norwegian village of Ask, in the municipality of Gjerdrum about 10 miles north of Oslo, at around 4 a.m. Wednesday. At least 10 people are being treated for injuries in a local hospital and several homes were swept away. At least one person is in critical condition, authorities said. “The situation is very dramatic. There has been a major landslide and we are in the process of evacuating residents from the area,” the local mayor, Anders Østensen, said Wednesday morning. “Several of them have lost their homes, and they are of course having a tough time. There are many who are very upset and scared.” The area around the village is known for its soft clay terrain that suddenly turns to liquid with fluctuating temperatures. Authorities are assessing whether it is safe for rescue crews to access the area.

Pandemic made my last year in office the hardest, says emotional Merkel (Reuters) Angela Merkel said in her last New Year’s address to the nation as German chancellor that 2020 was by far the most difficult of her 15-year leadership. “Let me tell you something personal in conclusion: in nine months a parliamentary election will take place and I won’t be running again,” said Merkel, 66. “Today is therefore in all likelihood the last time I am able to deliver a New Year’s address to you.” She added: “I think I am not exaggerating when I say: never in the last 15 years have we found the old year so heavy and never have we, despite all the worries and some scepticism, looked forward to the new one with so much hope.”

In new playground Dubai, Israelis find parties, Jewish rites (AP) It was a scene that just a few months ago would have been unthinkable. As Emiratis in flowing white robes and headdresses looked on, the Israeli bride and groom were hoisted on the shoulders of skullcap-wearing groomsmen and carried toward the dance floor, where dozens joined the throng swaying and singing in Hebrew. Noemie Azerad and Simon David Benhamou didn’t just throw a somewhat normal wedding bash in the middle of a pandemic that has shut down their country and ravaged the world. They were reveling in Dubai in the United Arab Emirates, which—like most of the Arab world—had been off-limits to Israeli passport holders for decades. The pair was among tens of thousands of Israelis who had flocked to the UAE in December after the two countries normalized ties in a breakthrough U.S.-brokered deal. Scores of Israeli tourists, seeking revelry and relief from monthslong virus restrictions and undeterred by their government’s warnings about possible Iranian attacks in the region, have celebrated weddings, bar mitzvahs and the eight-day Jewish festival of Hanukkah with large gatherings banned back home. “I expected to feel really uncomfortable here,” said 25-year-old Azerad, the Israeli bride, from the hotel ballroom, bathed in the glow of Dubai’s glittering skyline. “I feel like it’s Tel Aviv,” Azerad said of Dubai. “I hear Hebrew everywhere.”

Saudi-led coalition strikes at Yemen capital after attacks on Aden blamed on Houthis (Reuters) Saudi-led coalition warplanes struck targets in Yemen’s Houthi-held capital Sanaa on Thursday in retaliation for attacks in the southern port city of Aden the previous day that took place as officials in a government backed by Riyadh arrived there. Thursday’s coalition air strikes hit Sanaa airport and several other sites in and around the city, residents said. Loud blasts were heard and warplanes flew overhead for several hours, they said. Houthi-run Masirah television said the planes hit at least 15 locations in different districts in the capital. There were no immediate reports of casualties. Coalition air strikes have killed thousands, including many civilians, over the course of the war.

#headlines #news

0 notes

beekeepingfiji · 4 years

Text

Disease Survey of Honey Bees in Vanuatu - PHAMA Technical Report 34

New Post has been published on https://www.beekeepingfiji.com/?p=3987

Disease Survey of Honey Bees in Vanuatu - PHAMA Technical Report 34

An AusAID initiative is to increase exports of high value primary products from Pacific Island Countries (PICs). The Pacific Horticultural and Agricultural Market Access Program (PHAMA) is designed to address constraints to market access for primary production products, including honey and other bee products. PHAMA funded the current bee disease survey to support the growth of the beekeeping industry in Vanuatu by establishing the disease status of the local honey bees and using this information as a basis for quarantine regulations and market access negotiations.

The bee disease survey was carried out by Byron Taylor and Tony Roper, AsureQuality Limited, New Zealand, from 17–27 October 2012. The last bee disease survey conducted in Vanuatu was done by Bettesworth and Grueber in 2000.

Gilbert Gibson has the largest hive holding in Vanuatu, currently managing approximately 250 colonies. A second beekeeper, Ian Shaw, operates around 70 colonies, and a number of individuals operate less than 6 hives.

Apiary Industry in Vanuatu

It is estimated that there are around 400 managed colonies in Vanuatu, with 90% or more on Efate. The annual honey crop is approximately 5 tonnes per year, all of which is consumed within Vanuatu. The estimated consumption is around 10 tonnes, with the shortfall being made up with imports of honey from Australia and France (Gilbert Gibson, pers. comm.).

Gilbert Gibson has been beekeeping in Vanuatu for many years but has recently moved to full-time beekeeping. It is his hope to increase his current hive numbers to increase production for local consumption in the short term, with the potential to move into export markets in the long term.

In addition to European bees, the Asian Honey Bee (Apis cerana) has recently been discovered on Efate. It is unsure how long Apis cerana has been in Vanuatu but, judging by its distribution and comments from Gilbert Gibson, anywhere from 2 to 4 years is realistic.

A component of the current survey was to assess the spread of Apis cerana and, in particular, whether it is present on the islands of Espiritu Santo, Malekula and Tanna.

Currently, honey and other bee products entering New Zealand from a number of PICs must be accompanied by a zoosanitary certificate issued by the veterinary authority of the exporting country which certifies that:

The honey originates from that country; and

The country is free from European foulbrood (EFB) caused by Melissococcus pluton. 1

Vanuatu is not included on the list of PICs covered by this import health standard (IHS), so access to New Zealand would need to be separately negotiated.

New Zealand’s Ministry for Primary Industries (MPI), formerly the Ministry of Agriculture and Forestry, revised the IHS for Specified Processed Bee Products in June 2009. However, this standard is on hold while issues with a similar IHS for bee products from Australia are resolved.

European foulbrood (EFB)

EFB is a bacterial disease that affects the developing brood and is controlled in many countries by feeding antibiotics to beehives. EFB-causing bacteria can be transmitted in bee products, especially honey and pollen.

EFB disease has never been detected in Vanuatu or New Zealand but regular surveys by competent personnel, and reporting to international authorities, are required to confirm this status. EFB is present in Australia.

In addition, honey exported to the European Union must come from apiaries of known disease history. This usually means an apiary database is being maintained annual bee disease surveys are being carried out, and beekeepers are reporting on the presence of listed bee diseases.

The survey team inspected 193 beehives

The survey team inspected 193 beehives for bee diseases and pests, in particular EFB and its associated secondary bacterium Paenibacillus alvei.

Samples were also taken from 34 hives for testing for Deformed Wing Virus (DWV) and four known strains of Israeli Acute Paralysis Virus (IAPV), the microsporidian Nosema ceranae, the internal or tracheal mite Acarapis woodi and the external mites Varroa sp and Tropilaelaps.

All these diseases, except DWV, A. woodi and the external mites, were raised as pathogens of concern by the beekeeping industry in New Zealand following the risk analysis done by MPI to allow heat-treated honey from Australia into New Zealand. DWV was found in New Zealand in 2007, and A. woodi and the external mites Varroa sp and Tropilaelaps are not transmitted in honey.

Varroa destructor is endemic in New Zealand. Since the IHS was reviewed, MPI has confirmed the presence of P. alvei and Nosema ceranae in New Zealand. A nationwide survey, plus ongoing annual sampling and testing, has not detected the presence of IAPV in New Zealand, and it remains a bee disease of concern with New Zealand beekeepers (McFadden, Tham et al 2012).

Bees were tested for DWV, Nosema ceranae, the tracheal mite and Varroa spp and Tropilaelaps, in case Vanuatu is in a position to export live bees, queen cells or drone semen in the future. However, the presence of Apis cerana and Varroa jacobsoni could limit the export potential of this material.

No cases of EFB or American foulbrood (AFB) were detected, despite a case of AFB being discovered in the previous survey in 2000 and an additional case being discovered earlier this year by Mr Gilbert Gibson and Mr Nambo Moses. The recent find was in the same area as the original discovery in 2000.

American foulbrood (AFB)

AFB is one of the most widespread and serious honey bee diseases in the world. This disease is endemic in New Zealand and is controlled by inspection and total destruction of infected material.

Some approved beekeepers can recover infected equipment by dipping in paraffin wax heated to 1600C for at least 10 minutes. AFB is subject to a Pest Management Strategy in New Zealand. It is recommended that for Vanuatu, AFB is included in an annual surveillance program and that any infected material found is destroyed.

Varroa jacobsoni

Varroa jacobsoni was identified in European honey bee colonies during the survey. Samples of these mites were taken for morphological and molecular analysis, which confirmed the identification.

The survey in Vanuatu achieved a hive inspection rate of 48% and a hive sampling rate of 8.5%, from a population of approximately 400 hives. New Zealand has a target inspection rate of 1.4% of hives under its exotic honey bee disease surveillance program. However, all hives in New Zealand must be inspected for AFB disease each year by an approved beekeeper, which increases the possibility of beekeepers finding a notifiable exotic bee disease or pest.

The survey team inspected 46 apiaries and 21 feral colony locations. While there is no official apiary register, it is estimated that we inspected around 80% of managed apiaries, compared to New Zealand’s target surveillance rate of 2.6%.

Apis cerana (Asian Honey Bee)

Apis cerana was confirmed on Efate and the two nearby islands of Pele and Emao, which lie north of Efate. Four samples were collected (three from Efate and one from Emao) and submitted to the laboratory for testing. These colonies were subjected to a brood inspection where possible.

Apis cerana was not detected on Santo, Malekula or Tanna. Eradication of the Asian bees (Apis cerana) from Efate, Pele and Emao is not feasible; however, awareness raising measures such as posters at ports and pamphlets for commercial and recreational sailors could help to reduce the chance of the Asian bees spreading between islands.

Laboratory analysis of bee samples did not detect any cases of DWV and IAPV, the tracheal mite Acarapis woodi, or the external mites Varroa destructor and Tropilaelaps. The external mites Acarapis externus and Acarapis dorsalis were detected on many bees. These mites are common in New Zealand and are not known to cause any damage to honey bees.

Nosema ceranae

The microsporidian Nosema ceranae was detected by polymerase chain reaction (PCR) in 13 of the 24 apiaries tested (54%). Previous surveys did not test for the presence of Nosema ceranae, so it is unclear how long it has been present in Vanuatu. Nosema ceranae has only recently been confirmed in New Zealand using PCR technology. It is not known what effect, if any, this species of nosema is having on honey bees either in New Zealand or in Vanuatu.

EFB disease has never been reported in Vanuatu and no evidence of this disease was found during this survey or during past surveys. No cases of tracheal mites or the Small Hive Beetle were found. There was no evidence of the African honey bee (Apis mellifera scutellata) or the Cape honey bee (Apis mellifera capensis). These diseases or pests are not transmitted through honey.

Other minor diseases were reconfirmed as being present, such as both the greater and lesser wax moths (which exist in New Zealand). Various species of ants, cockroaches, centipedes and lizards living in or around hives were also found, but these are not transmitted live in honey.

The risk pathways into Vanuatu

The risk pathways into Vanuatu for an exotic honey bee disease or pest are considerable, with ongoing importation of honey from France and Australia, regular shipping and air flights from a number of countries, plus visiting cruise ships and yachts, which could have honey on board.

The number of tourists representing a risk visiting Vanuatu has dropped slightly in recent years but has grown considerably since the last survey was completed.

As an indication, the number of accommodation rooms available almost doubled from 800 to more than 1500 between 2005 and 2011 (http://www.tms.com.vu/statisitics1.html).

Importation of honey into Vanuatu

Importation of honey into Vanuatu is managed under the “Animal Importation and Quarantine Act, 1988” and the “Animal Importation and Quarantine Regulations, 1994”. These documents require that honey imports are accompanied by an import permit which states:

“Permission for import is granted under the following conditions:

Contain no substances harmful to human health;

Have been processed, prepared, packaged, and transported according to the required public health legislation in the country of origin;

Have been heat treated or pasteurised;

No raw honey or combs are permitted entry.”

In order to retain stability in the local market as honey production increases, it will be necessary to investigate export opportunities. Export to New Zealand is currently allowed from some PICs; however, Vanuatu is not included in this IHS.

If Vanuatu were to negotiate its own conditions, New Zealand would likely require similar conditions to those currently imposed on other PICs.

This includes attesting to the country of origin of the product and certifying that Vanuatu is free of EFB. A surveillance program to address this issue is recommended and discussed in more detail in the report.

This surveillance program could also support the negotiation of export protocols to other export markets.

Disease Survey of Honey Bees in Vanuatu – PHAMA Technical Report 34

Download Disease Survey of Honey Bees in Vanuatu – PHAMA Technical Report 34

Disease Survey of Honey Bees in Vanuatu – PHAMA Technical Report 34 Download

0 notes

gordonwilliamsweb · 3 years

Text

Backed by Millions in Public and Private Cash, Rapid Covid Tests Are Coming to Stores Near You

Scientists and lawmakers agree that over-the-counter covid tests could allow desk workers to settle back into their cubicles and make it easier to reopen schools and travel.

This story also ran on Fortune. It can be republished for free.

But even as entrepreneurs race their products to market, armed with millions of dollars in venture capital and government investment, the demand for covid testing has waned. Manufacturing and bureaucratic delays have also kept rapid tests from hitting store shelves in large numbers, though the industry was energized by the Food and Drug Administration’s greenlighting of two more over-the-counter tests Wednesday.

Corporate giants and startups alike plan to offer a dizzying array of test options, most costing between $10 and $110. Their screening accuracy varies, as does the way consumers get results: collection kits mailed back to a lab, devices synced with artificial intelligence-enabled apps on a smartphone that spit out results within 15 minutes, and credit card-sized tests with strips of paper that must be dipped into a chemical substance.

“At-home tests are one of the key steps to getting back to normal life,” said Andy Slavitt, a member of the White House COVID-19 Response Team, during a February briefing.

The Biden administration announced in March it will allocate $10 billion from the recently passed stimulus package for covid testing to expedite school reopenings, and earlier said it would invoke the Defense Production Act to manufacture more at-home tests. Separately, the federal government has already sent millions of Abbott Laboratories’ BinaxNOW rapid tests to states, and California, for instance, is giving 3 million of them to its most disadvantaged school districts for free.

Large employers, like Google, sports leagues and the federal government, have already shelled out millions to regularly test their workers. Amazon just received emergency use authorization from the FDA for its own covid test and home collection kit, which it intends to use for its employee screening program.

Individuals who want to buy over-the-counter tests can bill their health insurance plans, which are required by the federal government in most cases to fully cover covid tests that have been authorized by the FDA.

Everlywell, based in Austin, Texas, is an at-home diagnostic company that already sells its collection kit to consumers through its website and Walgreens, and will soon offer same-day delivery via DoorDash in a dozen cities. Dr. Marisa Cruz, Everlywell’s executive vice president of regulatory and clinical affairs, said buyers can seek reimbursement from their insurance plans for the kit’s $109 cost. The tests are also eligible for purchase with pretax dollars from health savings or flexible spending accounts, she said.

<![CDATA[ window.addEventListener('message', function(event) { if (typeof event.data['datawrapper-height'] !== 'undefined') { var iframes = document.querySelectorAll('iframe'); for (var chartId in event.data['datawrapper-height']) { for (var i=0; i

Even with vaccines, epidemiologists say, rapid tests are desperately needed because more testing, along with mask-wearing and physical distancing, will get people back in offices and classrooms and help catch cases that go undetected. A report by the Centers for Disease Control and Prevention found that, of people with active infections, 44% reported no symptoms.

But the market for over-the-counter tests is risky. Demand for testing has plunged dramatically since the height of the winter surge and may not rebound as more people are vaccinated.

“You clearly are at risk of missing the market,” said Michael Greeley, co-founder and general partner at Flare Capital Partners, a venture capital firm focused on health care technology.

But Douglas Bryant, president and CEO of Quidel Corp., remains unfazed, even after the diagnostics manufacturer’s testing demand dropped by about one-third in the past two months.

“The level of testing for people with symptoms and the ‘worried well,’ who see others getting tested and think they should, too, is subsiding,” Bryant said. “But once we start to get more people vaccinated, the government will move from campaigning to get people vaccinated to saying, ‘Please test yourself regularly so we can get back to work.’”

Quidel, headquartered in San Diego, recently unveiled its latest test, the QuickVue At-Home COVID-19 Test, which takes 10 minutes to detect the coronavirus by homing in on specific proteins, called antigens. The FDA authorized the test for over-the-counter use Wednesday, and Quidel plans to announce retail partners in the coming weeks.

The FDA said in mid-March it would speed the pipeline for “screening testing,” including at-home covid tests that don’t require consumers to have symptoms or a prescription.

In February, the Biden administration cut a $232 million deal with Ellume, whose rapid antigen test was authorized by the FDA in December. Paired with an app, the test takes 15 minutes to analyze after a nose swab.

The Australian company currently ships hundreds of thousands of test kits a week to the U.S. from its factory in Brisbane to large companies and the Department of Defense. It plans to be on the shelves of multiple pharmacies by the second half of the year and in one major retailer in April, said Dr. Sean Parsons, the company’s founder and CEO.

“We are going as fast as we can possibly go,” he said.

The main holdup for Ellume has been getting enough swabs for its production line. The company is building a factory in the U.S. to reduce international shipping costs and increase production.

Abbott, which dominates the rapid-test market, said in January it expects to sell 120 million BinaxNOW antigen tests to consumers in the first half of the year. People who take the test now must do so under observation by telemedicine platform eMed. But Abbott received authorization from the FDA this week for an over-the-counter version that won’t require remote observation or a prescription. The test will be available in U.S. stores in the coming weeks, the company said.

Throughout the pandemic, the government has depended heavily on medical device behemoth Abbott’s testing options. The company’s rapid-diagnostics arm alone has snared $673 million in federal contracts to combat the coronavirus, according to a ProPublica database. This includes bulk purchases made by the Defense Department, the national prison system, Immigration and Customs Enforcement, the State Department and former President Donald Trump's office.

But antigen tests sometimes report false negatives, particularly among people without symptoms, noted Dr. Jac Dinnes, who co-authored a review of 64 covid test studies. By comparison, polymerase chain reaction (PCR) tests — generally employed by commercial labs — are more sensitive. PCR tests search for the virus’s genetic material over multiple testing cycles, which magnifies what’s in the swab sample, requiring a much smaller viral load for detection.

Antigen tests are the basis for most at-home screening, but the FDA has also authorized two at-home options — made by Lucira Health and Cue Health — that use molecular processes similar to a PCR test.

Still, many experts support the widespread distribution of cheap, rapid tests, even if they aren’t as sensitive as lab-run alternatives, and see a demand. In Germany, the supermarket chain Aldi began selling rapid tests in early March, roughly $30 for a five-pack, and sold out within hours. One recent study found that if a pack of tests was mailed to every household in the U.S. — even assuming that up to 75% would go into the garbage — they would save thousands of lives and avert millions of infections.

“Don’t let perfect be the enemy of good,” said study co-author and Yale University professor A. David Paltiel. “This doesn’t have to work perfectly to make a huge difference.”

Some companies are working on rapid-testing options that more precisely read samples, such as Gauss.

The Menlo Park, California, health tech company, which before the pandemic created an artificial intelligence-based app to measure surgical blood loss in real time, aims to harness its expertise to improve on the basic antigen test. It took about a week for CEO Siddarth Satish to raise $30 million of venture capital last October.

Its covid-testing app uses facial recognition software to confirm that test-takers correctly swab their noses. The app provides step-by-step instructions and timers. After 15 minutes, an algorithm based on thousands of sample tests interprets the result — which displays as a colored line, as with a pregnancy test — using the phone’s camera.

Gauss and Cellex, which manufactures the Gauss tests, await FDA authorization. In the meantime, they have produced more than 1.5 million kits and struck deals with supermarket chain Kroger and e-pharmacy site Truepill to sell them for about $30.

“A huge part of the accuracy issue with rapid tests is that you have to visually interpret them,” Satish said. “Sometimes you get really faint lines, just like with a pregnancy strip, and there’s some guesswork.”

Lucira Health, based in Emeryville, California, uses something called loop-mediated isothermal amplification technology, which is similar to PCR tests in precision. In February, the company went public, raising $153 million largely to fund the manufacturing of its all-in-one testing kit, currently prescribed by doctors across the country. The kit comes with a nose swab and a vial of chemicals analyzed by a hand-held device — taking up to 30 minutes for results.

Kelly Lewis Brezoczky, Lucira’s executive vice president, envisions the test kit on the shelf in local pharmacies, perched next to the NyQuil. “I always like to tell people that it is as easy to use as toothpaste,” she said.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

Backed by Millions in Public and Private Cash, Rapid Covid Tests Are Coming to Stores Near You published first on https://nootropicspowdersupplier.tumblr.com/

0 notes